| Size | Price | Stock | Qty |
|---|---|---|---|
| 500mg |
|
||
| 1g |
|
||
| 5g |
|
||
| Other Sizes |
| Targets |
As a chemical reagent for oligonucleotide synthesis, DMT-2'-F-Bz-dA does not have a defined biological target. Its role is to serve as a building block for incorporating 2'-fluoro-2'-deoxyadenosine residues into synthetic DNA or RNA sequences. The 2'-fluoro modification enhances the nuclease resistance and binding affinity of oligonucleotides, making this monomer valuable for the synthesis of therapeutic nucleic acids including antisense oligonucleotides, siRNAs, and aptamers.
|
|---|---|
| ln Vitro |
In cell-free biochemical systems, this phosphoramidite monomer is incorporated into oligonucleotide sequences during solid-phase synthesis. The resulting modified oligonucleotides containing 2'-fluoro-2'-deoxyadenosine residues exhibit enhanced stability against nuclease degradation and improved binding affinity to complementary nucleic acid sequences. These properties make the monomer useful for the preparation of oligonucleotide therapeutics and molecular biology probes. The 2'-fluoro modification also increases the thermal stability of DNA-RNA duplexes.
|
| ln Vivo |
This compound does not exhibit direct cellular activity as it is a chemical synthesis reagent rather than a bioactive molecule. Oligonucleotides synthesized using this monomer can be delivered into cells for various functional studies. The 2'-fluoro modification enhances the metabolic stability of oligonucleotides in cellular environments, making them more effective for antisense and RNAi applications. Cellular uptake of modified oligonucleotides typically requires transfection reagents or conjugation to targeting ligands.
|
| Enzyme Assay |
The standard procedure for incorporating this phosphoramidite involves solid-phase oligonucleotide synthesis using standard phosphoramidite chemistry. The monomer is dissolved in anhydrous acetonitrile at 0.1 M concentration and coupled to the growing oligonucleotide chain using activator solutions such as tetrazole or 5-ethylthio-1H-tetrazole. Coupling times typically range from 2-5 minutes. Following chain assembly, the oligonucleotide is deprotected using ammonium hydroxide treatment to remove the benzoyl protecting group from the adenine base and the DMT group from the 5'-position.
|
| Cell Assay |
No cell-based experimental protocols are directly applicable to this phosphoramidite monomer as it is a chemical synthesis reagent. Oligonucleotides containing 2'-fluoro-2'-deoxyadenosine residues synthesized using this monomer can be evaluated in cell culture experiments. Typical protocols include transfection of modified oligonucleotides into mammalian cell lines at concentrations of 10-100 nM using lipid-based transfection reagents. Cells are incubated for 24-72 hours, and target gene knockdown is assessed by qRT-PCR or Western blotting. Cellular uptake and intracellular distribution can be analyzed by fluorescent labeling.
|
| Animal Protocol |
DMT-2'-F-Bz-dA is not administered to animals as it is a chemical intermediate for oligonucleotide synthesis. Oligonucleotides containing 2'-fluoro-2'-deoxyadenosine residues synthesized using this monomer may be evaluated in animal models for therapeutic applications. Typical studies involve administration of modified oligonucleotides to mice or rats via intravenous, subcutaneous, or intraperitoneal routes at doses of 1-30 mg/kg. Pharmacodynamic endpoints include target gene silencing in tissues and therapeutic efficacy in disease models.
|
| ADME/Pharmacokinetics |
As a chemical reagent, this compound does not have established pharmacokinetic properties. Oligonucleotides containing 2'-fluoro modifications exhibit enhanced metabolic stability compared to unmodified oligonucleotides. The 2'-fluoro modification increases resistance to nuclease degradation, resulting in longer plasma half-lives ranging from several hours to days. Biodistribution of modified oligonucleotides is predominantly to liver, kidney, and spleen. The presence of the fluorine atom may also influence tissue distribution and cellular uptake.
|
| Toxicity/Toxicokinetics |
The compound is not intended for therapeutic use and lacks established toxicity profiles. Standard laboratory safety precautions should be observed when handling this chemical reagent. Oligonucleotides containing 2'-fluoro modifications can exhibit improved safety profiles compared to unmodified oligonucleotides due to reduced immune stimulation and off-target effects. However, potential toxicities include hepatotoxicity and nephrotoxicity at high doses. Maximum tolerated doses depend on the specific oligonucleotide sequence and additional modifications.
|
| Additional Infomation |
DMT-2'-F-Bz-dA is a research-grade chemical supplied for oligonucleotide synthesis applications. It is not an approved pharmaceutical and has no clinical trial history. The compound is typically stored at -20°C under desiccated conditions to maintain stability. Purity specifications generally exceed 95% by HPLC analysis. 2'-Fluoro-modified oligonucleotides are widely used in therapeutic nucleic acid development. This product is for research use only and is not for human or veterinary therapeutic applications.
|
| Molecular Formula |
C38H34FN5O6
|
|---|---|
| Molecular Weight |
675.70
|
| Exact Mass |
675.249
|
| CAS # |
136834-21-4
|
| PubChem CID |
11125261
|
| Appearance |
White to light yellow solid powder
|
| LogP |
5.773
|
| Hydrogen Bond Donor Count |
2
|
| Hydrogen Bond Acceptor Count |
10
|
| Rotatable Bond Count |
11
|
| Heavy Atom Count |
50
|
| Complexity |
1060
|
| Defined Atom Stereocenter Count |
4
|
| SMILES |
COC1=CC=C(C=C1)C(C2=CC=CC=C2)(C3=CC=C(C=C3)OC)OC[C@@H]4[C@H]([C@H]([C@@H](O4)N5C=NC6=C(N=CN=C65)NC(=O)C7=CC=CC=C7)F)O
|
| InChi Key |
DDOOVEXTSRBCMU-VYUOYPLNSA-N
|
| InChi Code |
InChI=1S/C38H34FN5O6/c1-47-28-17-13-26(14-18-28)38(25-11-7-4-8-12-25,27-15-19-29(48-2)20-16-27)49-21-30-33(45)31(39)37(50-30)44-23-42-32-34(40-22-41-35(32)44)43-36(46)24-9-5-3-6-10-24/h3-20,22-23,30-31,33,37,45H,21H2,1-2H3,(H,40,41,43,46)/t30-,31-,33-,37-/m1/s1
|
| Chemical Name |
N-[9-[(2R,3R,4R,5R)-5-[[bis(4-methoxyphenyl)-phenylmethoxy]methyl]-3-fluoro-4-hydroxyoxolan-2-yl]purin-6-yl]benzamide
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 1.4799 mL | 7.3997 mL | 14.7995 mL | |
| 5 mM | 0.2960 mL | 1.4799 mL | 2.9599 mL | |
| 10 mM | 0.1480 mL | 0.7400 mL | 1.4799 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
